
World-leading MedTech company specializing in innovative wound care solutions, surgical products, gloves, and antiseptics for healthcare providers globally.
Import Shipments
Distribution Centers
Annual Revenue
Founded
Mölnlycke has been focusing on sustainable growth through innovation, digital transformation, and expanding its portfolio across wound care and surgical solutions while strengthening its commitment to environmental sustainability and Net Zero emissions goals.
Launched the Biogel Tech range in 2023, specifically designed gloves for critical environments such as pharmaceutical manufacturing facilities and research laboratories. Updated the WeCare sustainability roadmap in 2024 to prepare for the transition to Corporate Sustainability Reporting Directive with enhanced transparency in sustainability reporting. Achieved significant organic growth across all business areas in 2024, with Antiseptics delivering outstanding 23% growth and Wound Care reaching over EUR 1.2 billion in sales. Continued investment in renewable energy initiatives, achieving 100% renewable electricity usage across operations while reducing greenhouse gas emissions by 15% compared to 2021 baseline.
Strategic efforts to expand market presence and reach new customer segments.
Implementation of advanced technologies to improve service delivery and customer experience.
Mölnlycke Health Care operates as a global MedTech leader with a purpose to revolutionize care for people and planet. The company employs 8,617 people across 39 commercial entities and maintains 14 manufacturing sites in nine countries. With Wound Care representing 59% of total sales, Mölnlycke has established itself as a leading global provider of wound care products and therapy-based solutions. The company is owned by Patricia Industries, a part of Investor AB, which is listed on NASDAQ OMX Stockholm and was founded by the Wallenberg family in 1916.
Gothenburg, Sweden
1849
Private company